NeoGenomics, Inc. beat EPS estimates 88% of the time across 16 reported quarters (14 beats, 2 misses), averaging +26.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.01 | not reported | not reported | Q2 FY26 call · transcript |
| Q1 FY26 | $-0.08 | $-0.06 | +25.0% | Beat | |
| Q3 FY25 | $-0.07 | $-0.05 | +28.6% | Beat | |
| Q2 FY25 | $-0.07 | $-0.06 | +14.3% | Beat | Q2 FY25 call · transcript |
| Q1 FY25 | $-0.11 | $-0.08 | +27.3% | Beat | |
| Q4 FY24 | $-0.04 | $-0.02 | +50.0% | Beat | |
| Q3 FY24 | $-0.05 | $-0.02 | +60.0% | Beat | |
| Q2 FY24 | $-0.05 | $-0.04 | +20.0% | Beat | |
| Q1 FY24 | $-0.07 | $-0.08 | -14.3% | Miss | |
| Q4 FY23 | not reported | $-0.02 | not reported | not reported | |
| Q3 FY23 | $-0.11 | $-0.06 | +45.5% | Beat | |
| Q2 FY23 | $-0.15 | $-0.09 | +40.0% | Beat |
Back to NEO overview · NEO holders · NEO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.